Razman Aimi Zafira, Baharudin Noorhida, Mohd Kasim Noor Alicezah, Al-Khateeb Alyaa, Ismail Zaliha, Nawawi Hapizah
Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA, Sungai Buloh 47000, Selangor, Malaysia.
Department of Primary Care Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh 47000, Selangor, Malaysia.
Healthcare (Basel). 2022 Dec 5;10(12):2448. doi: 10.3390/healthcare10122448.
Dyslipidaemia is a major cause of morbidity and mortality. The aims of this study are to determine the prevalence of dyslipidaemia subtypes, the proportions of lipid-lowering therapy (LLT) use, and the achievement of low-density lipoprotein cholesterol (LDL-C) treatment targets for high-risk (HR) and very high-risk (VHR) Malaysians. This cross-sectional study involves 5279 participants across 11 states in Malaysia. The data were obtained through a standardised questionnaire, anthropometric measurements, venous glucose and lipid profile. The participants with existing cardiovascular disease (CVD) or diabetes with at least one of the other major risk factors (smoking, hypertension or dyslipidaemia) were grouped into the VHR category. Other participants were risk-categorised using the Framingham General CVD Risk Score (FRS-CVD). The prevalence of elevated LDL-C, LLT use and LDL-C target were set according to respective risk categories. Pearson's chi-squared test was used to test the difference in the proportions. The mean ± standard deviation (SD) age was 41.1 ± 14.8 years, and 62.2% (3283/5279) of the group were females. Within the participant group, 51.5% were found to have elevated total cholesterol, 28.8% had low HDL-C, and 33.8% had high triglyceride. As for elevated LDL-C, 9.8% were in VHR, 8.6% in HR, 5.8% in MR and 34.9% in LR categories. Among the VHR group, 75.8% were not on LLT, and only 15.9% achieved the LDL-C target. As for the HR category, 87.7% were not on LLT, and only 16.1% achieved the LDL-C target. Dyslipidaemia is highly prevalent among Malaysians. The majority of VHR and HR participants were not on LLT and did not achieve LDL-C treatment targets. Proactive programs are warranted to combat dyslipidaemia-associated CVD events in these groups.
血脂异常是发病和死亡的主要原因。本研究的目的是确定血脂异常亚型的患病率、降脂治疗(LLT)的使用比例,以及马来西亚高危(HR)和极高危(VHR)人群低密度脂蛋白胆固醇(LDL-C)治疗目标的达成情况。这项横断面研究涉及马来西亚11个州的5279名参与者。数据通过标准化问卷、人体测量、静脉血糖和血脂谱获得。患有现有心血管疾病(CVD)或糖尿病且伴有至少一项其他主要危险因素(吸烟、高血压或血脂异常)的参与者被归为VHR类别。其他参与者使用弗雷明汉心血管疾病综合风险评分(FRS-CVD)进行风险分类。根据各自的风险类别设定LDL-C升高、LLT使用情况和LDL-C目标的患病率。采用Pearson卡方检验来检验比例差异。平均年龄±标准差(SD)为41.1±14.8岁,该组中62.2%(3283/5279)为女性。在参与者组中,发现51.5%的人总胆固醇升高,28.8%的人HDL-C低,33.8%的人甘油三酯高。至于LDL-C升高,VHR类别中有9.8%,HR类别中有8.6%,中危(MR)类别中有5.8%,低危(LR)类别中有34.9%。在VHR组中,75.8%未接受LLT治疗,只有15.9%达到了LDL-C目标。至于HR类别,87.7%未接受LLT治疗,只有16.1%达到了LDL-C目标。血脂异常在马来西亚人中非常普遍。大多数VHR和HR参与者未接受LLT治疗,也未达到LDL-C治疗目标。有必要开展积极的项目来对抗这些人群中与血脂异常相关的CVD事件。